相似文献
1
New Paradigms in Antithrombotic Strategies: A Leap into the Future of Cardiovascular Medicine.
J Clin Med. 2022 May 10;11(10):2693. doi: 10.3390/jcm11102693.
2
Prevention of thrombotic disorders by antithrombotic diet and exercise: evidence by using global thrombosis tests.
Future Sci OA. 2018 Jan 24;4(4):FSO285. doi: 10.4155/fsoa-2017-0104. eCollection 2018 Apr.
3
Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats.
J Hepatol. 2013 Aug;59(2):358-66. doi: 10.1016/j.jhep.2013.03.027. Epub 2013 Mar 30.
4
Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs.
Curr Pharm Des. 2016;22(20):2926-46. doi: 10.2174/1381612822666160307150454.
5
Interactions of antithrombotic herbal medicines with Western cardiovascular drugs.
Pharmacol Res. 2020 Sep;159:104963. doi: 10.1016/j.phrs.2020.104963. Epub 2020 Jun 1.
6
Emerging nanotherapeutics for antithrombotic treatment.
Biomaterials. 2020 Oct;255:120200. doi: 10.1016/j.biomaterials.2020.120200. Epub 2020 Jun 12.
7
Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction.
JAMA. 2015 Feb 24;313(8):805-14. doi: 10.1001/jama.2015.0809.
8
Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome.
J Clin Med. 2022 Sep 23;11(19):5605. doi: 10.3390/jcm11195605.
9
Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus.
Circulation. 2020 Dec;142(22):2172-2188. doi: 10.1161/CIRCULATIONAHA.120.045465. Epub 2020 Nov 30.
10
Management of antithrombotic treatment and bleeding disorders in patients requiring venous access devices: A systematic review and a GAVeCeLT consensus statement.
J Vasc Access. 2022 Jul;23(4):660-671. doi: 10.1177/11297298211072407. Epub 2022 May 9.
本文引用的文献
1
Temporal trends and patterns in atrial fibrillation incidence: A population-based study of 3·4 million individuals.
Lancet Reg Health Eur. 2022 Apr 25;17:100386. doi: 10.1016/j.lanepe.2022.100386. eCollection 2022 Jun.
2
Prevalence of New-Onset Atrial Fibrillation and Associated Outcomes in Patients with Sepsis: A Systematic Review and Meta-Analysis.
J Pers Med. 2022 Mar 30;12(4):547. doi: 10.3390/jpm12040547.
3
Prevalence and Rate of Resolution of Left Atrial Thrombus in Patients with Non-Valvular Atrial Fibrillation: A Two-Center Retrospective Real-World Study.
J Clin Med. 2022 Mar 10;11(6):1520. doi: 10.3390/jcm11061520.
4
Anticoagulation Prior to COVID-19 Infection Has No Impact on 6 Months Mortality: A Propensity Score-Matched Cohort Study.
J Clin Med. 2022 Jan 12;11(2):352. doi: 10.3390/jcm11020352.
5
Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Non-Valvular Atrial Fibrillation Patients: Results of A Real-World Study in a Metropolitan Area of Northern Italy.
J Clin Med. 2021 Sep 30;10(19):4536. doi: 10.3390/jcm10194536.
6
A Review of Current and Future Antithrombotic Strategies in Surgical Patients-Leaving the Graduated Compression Stockings Behind?
J Clin Med. 2021 Sep 22;10(19):4294. doi: 10.3390/jcm10194294.
7
Abelacimab for Prevention of Venous Thromboembolism.
N Engl J Med. 2021 Aug 12;385(7):609-617. doi: 10.1056/NEJMoa2105872. Epub 2021 Jul 19.
8
Prevalence and Impact of Atrial Fibrillation in Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis.
J Clin Med. 2021 Jun 4;10(11):2490. doi: 10.3390/jcm10112490.
9
Inappropriate Use of Oral Antithrombotic Combinations in an Outpatient Setting and Associated Risks: A French Nationwide Cohort Study.
J Clin Med. 2021 May 27;10(11):2367. doi: 10.3390/jcm10112367.
10
Interplay between inflammation and thrombosis in cardiovascular pathology.
Nat Rev Cardiol. 2021 Sep;18(9):666-682. doi: 10.1038/s41569-021-00552-1. Epub 2021 May 6.
Zotero 插件